Tavaborole
4 NDCs across 4 manufacturers|4 Generic,0 Brand
Tavaborole is used to treat onychomycosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 7, 2014, and the first generic was approved Oct 13, 2020. FDA's Orange Book lists 4 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $20 million on Tavaborole across 34,000 claims for 11,000 beneficiaries.
Tavaborole is available as 4 NDCs from 4 manufacturers (4 generic, 0 brand), with NADAC prices from $3.39 to $3.57 per ML — a 5% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
4
4G / 0B
Manufacturers
4
competing in market
Price Spread
$3.39 – $3.57
per ML
7d Activity
avg -2.9% WoW · of 4 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Cipla USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Oxaborole Antifungal class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
4 manufacturers producing TAVABOROLE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
TAVABOROLE 5% TOPICAL SOLUTION | $3.5669 per ML | — |
TAVABOROLE 5% TOPICAL SOLUTION | $3.3901 per ML | -2.87% |
TAVABOROLE 5% TOPICAL SOLUTION | $3.3901 per ML | -2.87% |
TAVABOROLE 5% TOPICAL SOLUTION | $3.3901 per ML | -2.87% |
Frequently Asked Questions
What is Tavaborole used to treat?
Tavaborole is used to treat onychomycosis, per the National Library of Medicine's MED-RT classification.
When did Tavaborole become available as a generic?
FDA approved the first generic Tavaborole (ANDA) on Oct 13, 2020. The Orange Book currently lists 4 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Tavaborole?
In 2024, Medicare Part D spent $20 million on Tavaborole across 34,000 claims for 11,000 beneficiaries.
How many Tavaborole products are on the market?
The Tavaborole drug market contains 4 NDCs from 4 manufacturers — 4 generic and 0 brand products.
What is the price range for Tavaborole?
NADAC reference prices for Tavaborole range from $3.3901 to $3.5669 per ML — a 5% difference between cheapest and most expensive.
Which manufacturers make Tavaborole?
4 manufacturers list Tavaborole in NADAC. Ranked by number of NDCs, the largest are Cipla USA Inc. (1), Chartwell RX LLC (1), Alembic Pharmaceuticals Inc. (1), Viona Pharmaceuticals Inc. (1).
How has the price of Tavaborole changed recently?
Over the past 7 days, 0 Tavaborole NDCs rose and 3 fell, with a market-wide average change of -2.9%.